Ultrasound examination of extensive limb swelling reactions after diphtheria-tetanus-acellular pertussis or reduced-antigen content diphtheria-tetanus-acellular pertussis immunization in preschool-aged children

Pediatrics

Volumn 118, Issue 4, 2006, Pages 1501-1509

  Marshall, Helen Siobhan ^a,b   Gold, Michael Steven ^a,b   Gent, Roger ^a   Quinn, Patrick John ^a,b   Piotto, Lino ^a   Clarke, Michelle Frances ^a   Roberton, Donal Muir ^a,b  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Adverse events; Diphtheria; Local reaction; Pertussis; Tetanus; Ultrasound

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PARACETAMOL; BACTERIAL ANTIGEN;

ARM SWELLING; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DRUG DOSAGE FORM COMPARISON; FEMALE; FUNCTIONAL DISEASE; HUMAN; IMMUNIZATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN REDNESS; TETANUS; ULTRASOUND; ARM; CHEMICALLY INDUCED DISORDER; CHILD; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; EDEMA; HOSPITALIZATION; PATHOLOGY; PROSPECTIVE STUDY;

ANTIGENS, BACTERIAL; ARM; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DOUBLE-BLIND METHOD; EDEMA; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 33750112672     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2890     Document Type: Article

References (23)

1. Bonhoeffer J, Kohl K, Chen R, et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine. 2002;21:298-302
2. National Health and Medical Research Council. The Australian Immunisation Handbook. 7th ed. Canberra, Australia: Australian Government Publishing Service; 2000
3. Gold MS, Noonan S, Osbourn M, Precepa S, Kempe AE. Local reactions after fourth dose of acellular pertussis vaccine in South Australia. Med J Aust. 2003;179:191-194
4. Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics. 2000;105(1). Available at: www.pediatrics.org/cgi/content/ full/105/1/e12
5. Centers for Disease Control and Prevention. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-13):1-8
6. Scheifele DW, Meekison W, Grace M, et al. Adverse reactions to the preschool (fifth) dose of absorbed diphtheria-pertussis-tetanus vaccine in Canadian children. Can Med Assoc J. 1991;145:641-647
7. Halperin S, Scheifele D, Barreto L, et al. Comparison of a fifth dose of a five-component acellular or whole-cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J. 1999;18:772-779
8. Pichichero M, Edwards K, Anderson E, et al. Safety and immunogenicity of six acellular pertussis vaccines and one wholecell pertussis vaccine given as a fifth dose in four to six year old children. Pediatrics. 2000;105:1-8
9. Woo E, Burwen D, Gatumu S, Ball R, Vaccine Adverse Event Reporting System Working Group. Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System. Clin Infect Dis. 2003;37:351-358
10. Skowronski D, Remple V, Macnabb J, et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity and anticipated impact. Pediatrics. 2003;112(6). Available at: www.pediatrics.org/cgi/ content/full/112/6/e453
11. Adverse Drug Reactions Advisory Committee. Extensive limb swelling and DTPa booster doses. Aust Adverse Drug React Bull. 2001;20:10
12. Rennels M. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis J. 2003;14:196-198
13. Rennels M, Deloria M, Pichichero M, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics. 2000;105:1-6
14. National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. Canberra, Australia: Australian Government Publishing Service; 2003
15. Rowe J, Yerkovich ST, Richmond P, et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect Immun. 2005;73:8130-8135
16. Kosuwon P, Warachit B, Hutagalung Y, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year old children primed with four doses of whole-cell pertussis vaccine. Vaccine. 2003;21:4194-4200
17. Cook IF, Murtagh J. Needle length required for intramuscular vaccination of infants and toddlers: an ultrasonographic study. Aust Fam Physician. 2002;31:295-297
18. Groswasser J, Kahn A, Bouche B, Hanquinet S, Perlmuter N, Hessel L. Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness. Pediatrics. 1997;100:400-403
19. Poland GA, Borrud A, Jacobson RM, et al. Determination of deltoid fat pad thickness: implications for needle length in immunization. JAMA. 1997;277:1709-1711
20. Marshall H, Nolan T, Roberton D, et al. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years. Vaccine. 2006;24:6120-6128
21. Jacquet JM, Bégué P, Grimprel E, et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine. 2006;24:2440-2448
22. Scheifele D, Halperin S, Ochnio J, et al. A modified vaccine reduces the rate of large local injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine. Pediatr Infect Dis J. 2005;24:1059-1066
23. Salmaso S, Mastrantonio P, Tozzi A, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics. 2001;108(5). Available at: www.pediatrics.org/cgi/content/full/108/5/e81